Filing Details
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) filed a Form 8-K with the Securities and Exchange Commission on July 21, 2026, disclosing a material event.
8k filedNASDAQ:CVKD
Cadrenal Therapeutics, Inc. (CVKD) Reports Material Event to SEC
Filing Details Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) filed a Form 8-K with the Securities and Exchange Commission on July 21, 2026, disclosing a material event. Market Context…
Market Context
Cadrenal Therapeutics, Inc.'s stock currently trades at $2.17 with a market capitalization of $22.8M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Cadrenal Therapeutics, Inc.'s stock.
All SEC filings for Cadrenal Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CVKD Stock Page
Frequently Asked Questions
Where can I read CVKD's SEC filings?
Browse all filings on our CVKD SEC filings page.
What types of SEC filings does Cadrenal Therapeutics, Inc. file?
Public companies like Cadrenal Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.